Global Cord Blood Corporation (NYSE: CORBF) is a biotechnology company specializing in the collection, processing and long-term storage of umbilical cord blood and cord tissue stem cells. Headquartered in Shenzhen, China, the company operates a network of accredited laboratories and storage facilities across the Asia-Pacific region, including mainland China, Singapore, Malaysia and Vietnam. By leveraging advanced cryopreservation techniques, Global Cord Blood offers parents the opportunity to secure a unique source of hematopoietic and mesenchymal stem cells for potential future therapeutic use.
The company’s core services encompass a turnkey solution that begins with the provision of collection kits and continues through on-site training for hospital staff, laboratory processing, quality control testing and secure cryogenic storage. Global Cord Blood adheres to international quality standards, holding certifications from organizations such as the Foundation for the Accreditation of Cellular Therapy (FACT) and the American Association of Blood Banks (AABB). In addition to its flagship private cord blood banking service, the company collaborates with research institutions and biotechnology firms to explore novel cell-based therapies across oncology, autoimmune and genetic disorders.
Founded in 2002, Global Cord Blood has evolved from a single processing laboratory into one of the region’s largest privately-held cord blood banks before its public listing. Over the years, it has forged strategic alliances with leading maternity hospitals and medical centers, expanded its product portfolio to include placental tissue preservation and invested in proprietary platforms for stem cell viability assessment. The company’s growth has been driven by rising awareness of regenerative medicine and increasing demand for personalized healthcare solutions among expectant parents in emerging markets.
Leadership at Global Cord Blood is headed by President and Chief Executive Officer Dr. Li Wang, whose background in stem cell research has guided the company’s R&D initiatives and international expansion. Chief Operating Officer Amy Chen oversees laboratory operations and quality assurance, while Chief Financial Officer Michael Liang manages fiscal strategy and investor relations. The board of directors includes seasoned clinicians and life sciences executives who collectively bring deep expertise in translational medicine, regulatory compliance and global healthcare markets.
AI Generated. May Contain Errors.
